Novel Findings on Activation of PD1/PD-L1 that Contributes to Cancer Development and Metastasis

XIE Liye; FU Jiejun; LU Yi; ZHANG Jian

doi:10.3971/j.issn.1000-8578.2017.17.0087

Cancer Research on Prevention and Treatment > 2017 > 44(6): 423-427. > DOI: 10.3971/j.issn.1000-8578.2017.17.0087

XIE Liye, FU Jiejun, LU Yi, ZHANG Jian. Novel Findings on Activation of PD1/PD-L1 that Contributes to Cancer Development and Metastasis[J]. Cancer Research on Prevention and Treatment, 2017, 44(6): 423-427. DOI: 10.3971/j.issn.1000-8578.2017.17.0087

Citation:

PDF (1830 KB)

Novel Findings on Activation of PD1/PD-L1 that Contributes to Cancer Development and Metastasis

XIE Liye¹,
FU Jiejun¹,
LU Yi^1, ,,
ZHANG Jian^{1, 2, 3, ,}

1.
Center for Translational Medicine, Guangxi Medical University, Key Laboratory of Longevity and Ageing-related Diseases, Ministry of Education, Nanning 530021, China
2.
School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China
3.
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15232, USA

More Information

Corresponding author:
LU Yi, E-mail: luyi5555@hotmail.com

ZHANG Jian, E-mail:jianzhang008@hotmail.com
Received Date: February 02, 2017
Revised Date: April 15, 2017
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Programmed cell death protein-1 (PD1) and programmed cell death protein-1 ligand 1 (PD-L1) act as important negative immune regulators. Combining PD1 receptors on T cells with their corresponding ligands PD-L1 on tumor cells can inhibit T cell activation and lead to tumor cell immune escape and resistance to conventional chemotherapy. In recent years, the drugs targeting PD1/PD-L1 monoclonal antibodies have achieved promising effects in various tumor types including non-small cell lung carcinoma and melanoma. They also dramatically improved poor prognosis and overall survival of some tumor patients. In this review, we will summerize the novel findings on the activation of PD1/PD-L1 in tumor occurrence, development and metastasis, as well as the updated clinical progress of using anti-PD1 or anti-PD-L1 in tumor immunotherapy.
- PD1,
- PD-L1,
- Cancer development,
- Metastasis,
- Immunotherapy

FullText(HTML)

References (37)

References

[1]	Ishida Y, Agata Y, Shibahara K. et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11): 3887-95. https://www.ncbi.nlm.nih.gov/pubmed?term=%22The+EMBO+journal%22%5BJour%5D+AND+11%5Bvolume%5D+AND+3887%5Bpage%5D+AND+1992%5Bpdat%5D&cmd=detailssearch
[2]	Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5(12): 1365-9. doi: 10.1038/70932
[3]	Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800. https://mayoclinic.pure.elsevier.com/en/publications/tumor-associated-b7-h1-promotes-t-cell-apoptosis-a-potential-mech
[4]	Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192(7): 1027-34. doi: 10.1084/jem.192.7.1027
[5]	Böger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients[J].Oncotarget, 2016, 7(17): 24269-83. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029700/
[6]	Iraolagoitia XL, Spallanzani RG, Torres NI, et al. NK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1/PD-L1 interactions with dendritic cells[J]. J Immunol, 2016, 197(3): 953-61. doi: 10.4049/jimmunol.1502291
[7]	Liu H, Bakthavatsalam R, Meng Z, et al. PD-L1 signal on liver dendritic cells is critical for Foxp3(+)CD4(+)CD25(+) Treg and liver tolerance induction in mice[J]. Transplant Proc, 2013, 45(5): 1853-5. doi: 10.1016/j.transproceed.2013.03.015
[8]	Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol, 2001, 2(3): 261-8. doi: 10.1038/85330
[9]	Stempin CC, Motran CC, Aoki MP, et al. PD-L2 negatively regulates Th1-mediated immunopathology during Fasciola hepatica infection[J]. Oncotarget, 2016, 7(47): 77721-31. https://www.researchgate.net/publication/309361654_PD-L2_negatively_regulates_Th1-mediated_immunopathology_during_Fasciola_hepatica_infection
[10]	Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost[J].Nature, 2014, 515(7528): 496-8. doi: 10.1038/515496a
[11]	Koh YW, Jeon YK, Yoon DH, et al. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma[J]. Tumour Biol, 2016, 37(6): 7507-14. doi: 10.1007/s13277-015-4622-5
[12]	Wang X, Sun Q, Liu Q, et al. CTC immune escape mediated by PD-L1[J]. Med Hypotheses, 2016, 93: 138-9. doi: 10.1016/j.mehy.2016.05.022
[13]	Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells[J]. Mol Oncol, 2015, 9(9): 1773-82. doi: 10.1016/j.molonc.2015.05.009
[14]	Aktas B, Bankfalvi A, Heubner M, et al. Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(R), clinicopathological markers and tumor cell dissemination in the blood and bone marrow[J]. Mol Clin Oncol, 2013, 1(6): 1049-54.
[15]	Chen YY, Wang LB, Zhu HL, et al. Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients[J]. Chin Med Sci J, 2013, 28(3): 147-51. doi: 10.1016/S1001-9294(13)60040-1
[16]	Zhou SL, Zhou ZJ, Hu ZQ, et al. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3beta/Snail signaling[J]. Cancer Lett, 2015, 358(2): 124-35. doi: 10.1016/j.canlet.2014.11.044
[17]	Steele CW, Karim SA, Leach JD, et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma[J]. Cancer Cell, 2016, 29(6): 832-45. doi: 10.1016/j.ccell.2016.04.014
[18]	Trojan J, Sarrazin C. Complete response of hepatocellular carcinoma in a patient with end-stage liver disease treated with nivolumab: whishful thinking or possible?[J]. Am J Gastroenterol, 2016, 111(8): 1208-9. doi: 10.1002/hep.27443/full?scrollTo=references
[19]	Mehta A, Gupta A, Hannallah F, et al. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma[J]. Melanoma Res, 2016, 26(3): 319-20. doi: 10.1097/CMR.0000000000000251
[20]	Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(7): 976-83. doi: 10.1016/S1470-2045(16)30053-5
[21]	Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(1): 23-34. doi: 10.1056/NEJMoa1504030
[22]	Atkins MB, Philips GK. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)[J]. Expert Opin Emerg Drugs, 2016, 21(3): 243-54. doi: 10.1080/14728214.2016.1226798
[23]	Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma[J]. Nat Commun, 2016, 7: 12624. doi: 10.1038/ncomms12624
[24]	Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528): 563-7. doi: 10.1038/nature14011
[25]	Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phaseⅡtrial[J].J Clin Oncol, 2013, 31(33): 4199-206. doi: 10.1200/JCO.2012.48.3685
[26]	Guo Z, Wang H, Meng F, et al. Combined trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer[J]. J Transl Med, 2015, 13: 247. doi: 10.1186/s12967-015-0613-y
[27]	Seyedin SN, Schoenhals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy[J]. Immunotherapy, 2015, 7(9): 967-80. doi: 10.2217/imt.15.65
[28]	Sagiv-Barfi I, Kohrt HE, Czerwinski DK, et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK[J]. Proc Natl Acad Sci U S A, 2015, 112(9): E966-72. doi: 10.1073/pnas.1500712112
[29]	Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial[J]. Ann Oncol, 2017, 28(4): 874-81.] doi: 10.1093/annonc/mdx008
[30]	Mok T, Schmid P, Aren O, et al. 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC[J]. J Thorac Oncol, 2016, 11(4 Suppl): S140-1. https://www.ncbi.nlm.nih.gov/pubmed/?term=tremelimumab
[31]	Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J].Lancet Oncol, 2016, 17(7): 883-95. doi: 10.1016/S1470-2045(16)30098-5
[32]	Atezolizumab (Tecentriq) for bladder cancer and NSCLC[J].Med Lett Drugs Ther, 2017, 59(1515): e40-1.
[33]	Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(10): 1374-85. doi: 10.1016/S1470-2045(16)30364-3
[34]	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-65. doi: 10.1016/S0140-6736(16)32517-X
[35]	Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920-8. doi: 10.1158/1078-0432.CCR-16-1741
[36]	Allard B, Pommey S, Smyth MJ, et al. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs[J].Clin Cancer Res, 2013, 19(20): 5626-35. doi: 10.1158/1078-0432.CCR-13-0545
[37]	Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(25): 2969-79. doi: 10.1200/JCO.2016.66.9861

[1]	DAI Nan, ZHAO Xiaolong, DAI Xiaoyan, LI Mengxia. Effect of Exosomal APE1 on Sensitivity of NSCLC A549 Cells to Cisplatin[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 492-497. DOI: 10.3971/j.issn.1000-8578.2020.19.1609
[2]	HUANG Zejian, FANG Chang, YU Baodan, CHENG Qing, LYU Ping. 3E10 Targeting CD24 Enhances Chemotherapy Sensitivity of Hepatocellular Carcinoma HuH-7 Cells[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 540-544. DOI: 10.3971/j.issn.1000-8578.2018.17.1484
[3]	CAI Rui, CHEN Qiuqiu, JIANG Wei. 5-azacytidine Increases Radiation Sensitivity of Nasopharyngeal Carcinoma Cell Line C666-1[J]. Cancer Research on Prevention and Treatment, 2017, 44(2): 94-97. DOI: 10.3971/j.issn.1000-8578.2017.02.003
[4]	ZHANG Juping, SHI Yehui, JIA Yongsheng, ZHOU Liyan, TONG Zhongsheng. GDF11 is Involved in Human Hepatic Carcinoma Cells SMMC-7721 Proliferation and Sensitivity to DDP[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 459-462. DOI: 10.3971/j.issn.1000-8578.2016.06.005
[5]	LI Wei, PENG Junqin, LI Jiansheng, TANG Rijie. MR Apparent Diffusion Coefficient Predicts Sensitivity of Nasopharyngeal Carcinoma to Radiotherapy and Related Factors[J]. Cancer Research on Prevention and Treatment, 2015, 42(12): 1221-1226. DOI: 10.3971/j.issn.1000-8578.2015.12.011
[6]	HU Lili, YIN Yanjun, ZHONG Wenjuan, QIU Feng. miR-200c Enhances Sensitivity of Lung Cancer Cell A549 to Paclitaxel and Gefitinib and Related Mechanism[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 760-764. DOI: 10.3971/j.issn.1000-8578.2015.08.003
[7]	CAO Xinmei, ZHANG Daiquan, XIA Jiyi, WANG Xu, GAO Yan, XIONG Wei. Effects of HER2 shRNA on Chemotherapy Sensitivity of Mouse Lewis Cells[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 366-368. DOI: 10.3971/j.issn.1000-8578.2014.05.004
[8]	Yang Qingshan, Liu Yuanyuan, Jiang Lipeng. Effect of Expression Vector of Human BAG-1 Gene on Radio-sensitivity of Lung Adenocarcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2012, 39(02): 127-129. DOI: 10.3971/j.issn.1000-8578.2012.02.002
[9]	FANG Chuan, TAN Yan-li, WANG Jia-liang, SHI Yan-fang, SHAN Xiao-song, LI Wei. Primary Culture and Drug Sensitivity of Human Glioma Cells[J]. Cancer Research on Prevention and Treatment, 2010, 37(12): 1380-1382. DOI: 10.3971/j.issn.1000-8578.2010.12.012
[10]	ZHANG Wei, GU Min. Geldanamycin Sensitizes Human Breast Cancer Cells to Adriamycin both in vitro and in vivo[J]. Cancer Research on Prevention and Treatment, 2010, 37(10): 1109-1112. DOI: 10.3971/j.issn.1000-8578.2010.10.004

Cited By

Cited by

Periodical cited type(9)

1.	成俊，徐雪峰，李伟. D-CBCT在肺癌容积旋转调强计划精准治疗中的临床应用. 中国CT和MRI杂志. 2024(04): 35-37 .
2.	蒋浩，曹新超，吴桐，郭志斌. 低剂量CT联合外周血循环肿瘤细胞在肺癌早期诊断中的价值研究. 中国CT和MRI杂志. 2024(06): 57-60 .
3.	王晶，翟成凯. 肿瘤自身抗体及CT人工智能在NSCLC早期诊断中的应用研究进展. 解放军医学杂志. 2024(07): 848-854 .
4.	李雪娇. 多排螺旋CT低剂量胸部扫描在肺癌早期筛查中的应用价值分析. 医药前沿. 2024(15): 79-81 .
5.	易梅玲，易芳玲. 双层探测器光谱CT智能剂量调控技术在低剂量胸部体检中的应用价值. 中国医疗器械信息. 2024(22): 8-10+81 .
6.	杏子，彭源. 低剂量CT在肺癌筛查中的价值. 中国防痨杂志. 2024(S2): 234-236 .
7.	陈蔚，蒋伟. 低剂量螺旋CT扫描用于肺癌筛查及鉴别的效果评估. 深圳中西医结合杂志. 2023(01): 71-73 .
8.	慕珂珂，肖凌云，董炎红. 早期肺癌患者血清和胸腔积液中CYFRA211、NSE及SCC水平变化及意义. 中国实用医刊. 2023(09): 34-37 .
9.	陈彪. 低剂量螺旋CT联合血清肿瘤标志物在肺癌诊断中的临床应用价值. 影像研究与医学应用. 2023(22): 24-26 .

Other cited types(1)

Get Citation

PDF

XML

Article views (2445) PDF downloads (4371) Cited by(10)

Turn off MathJax

Article Contents

Abstract

References

Novel Findings on Activation of PD1/PD-L1 that Contributes to Cancer Development and Metastasis